Prostate Cancer Risk Stratification in NRG Oncology Phase III...
Current clinical risk stratification methods for localized prostate cancer are suboptimal, leading to over- and undertreatmen [...]
Artera Receives California Lab License, Expanding Access to its...
Clinicians and patients in California can now access personalized, actionable insights to inform prostate cancer treatment de [...]
AI-Powered Prostate Cancer Risk Assessment Tool Validated for Low-risk...
Alicia Morgans interviews Andre Esteva about ArteraAI's expanded prostate cancer test, now validated for low-risk and active [...]
SUO Annual Meeting
The 25th Annual Scientific Meeting in Urologic Oncology will be held December 4 – 6, 2024, at the Sheraton Dallas Hotel.
LUGPA Annual Meeting
LUGPA’s Annual Meeting is the premiere education and networking event for independent urology practice physicians, administra [...]
Artera Announces Two Presentations at ASTRO 2024 Validating its...
Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present [...]
MedCity Pivot Podcast: How AI Can Help in Cancer
Dr. Timothy Showalter talks about how AI can be a powerful force in recommending treatment for cancer patients. He is Artera' [...]
Artera Product Webinar – August
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating localized prostate cancer. Watch th [...]